Sheffield Institute for
Translational Neuroscience


SITraN Communications
Rebecca Brown
T: +44 (0)114 222 2261

Latest News


Promising MND drug helps slow disease progression and benefits patients physically

A phase 3 clinical genetic therapy trial led by Prof Dame Pamela Shaw and Prof Chris McDermott in the UK to treat the SOD1-linked subtype of motor neurone disease (MND) could be a turning point for patient care, after the results showed significant physical benefits for patients after 12 months.

Read more


World Parkinson's Day - UK Parkinson’s Clinical Study Group

Today (11th April) is World Parkinson’s Day. Parkinson’s is the fastest growing neurological condition in the world, 1 in 37 people alive today in the UK will be diagnosed with Parkinson’s in their lifetime. Annual costs resulting from Parkinson’s exceed $ 50 Billion dollars in the US alone.

Read more


Innovative gene therapy programme paves the way for new treatments for neurodegenerative diseases

An innovative gene therapy programme which could pave the way for novel treatments for neurodegenerative diseases, has been launched at the University of Sheffield in collaboration with the Cell and Gene Therapy Catapult. 

Read more


Frequent strenuous exercise increases the chance of developing MND in genetically at risk individuals

Scientists at the University of Sheffield believe the pioneering study represents a significant step towards unravelling the link between high levels of physical activity and the development of the neurodegenerative condition which affects approximately 5,000 people in the UK.

Read more


​​​​​​​New gene therapy innovation centre to advance scientific discoveries into life-changing treatments

A pioneering gene therapy innovation centre at the University of Sheffield is set to advance scientific discoveries into promising treatment options for millions of patients with life-threatening diseases. 

Read more

RSS Icon

SITraN seminar series